`
`- VOLUME 4 -
`IN THE UNITED STATES DISTRICT COURT
`IN AND FOR THE DISTRICT OF DELAWARE
`NOVARTIS PHARMACEUTICALS
`CIVIL ACTION
`CORPORATION and NOVARTIS
`AG,
`Plaintiffs,
`
`NO. 14-1043 (RGA)
`CIVIL ACTION
`
`NO. 14-1196 (RGA)
`CIVIL ACTION
`
`NO. 14-1289 (RGA)
`
`:::::::::::::::::::::::::::::::
`
`vs.
`BRECKENRIDGE
`PHARMACEUTICALS INC.,
`Defendant.
`------------------------
`NOVARTIS PHARMACEUTICALS
`CORPORATION and NOVARTIS
`AG,
`Plaintiffs,
`
`vs.
`ROXANE LABORATORIES,
`INC.,
`Defendant.
`------------------------
`NOVARTIS PHARMACEUTICALS
`CORPORATION and NOVARTIS
`AG,
`Plaintiffs,
`
`vs.
`PAR PHARMACEUTICAL,
`INC.,
`Defendant.
`
`Wilmington, Delaware
`Thursday, September 1, 2016
`8:30 o'clock, a.m.
`- - -
`BEFORE: HONORABLE RICHARD G. ANDREWS, U.S.D.C.J.
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`
`NOVARTIS EXHIBIT 2132
`Par v Novartis, IPR 2016-00084
`Page 1 of 3
`
`
`
`P R O C E E D I N G S
`
`1205
`
`(Proceedings commenced in the courtroom,
`beginning at 8:30 a.m.)
`
`Good
`All right.
`THE COURT:
`Please be seated.
`Let's continue.
`MR. ZULLOW:
`May we call our next
`
`morning.
`
`witness?
`
`Yes.
`Defendants call Dr.
`
`THE COURT:
`MR. ZULLOW:
`Tullius to the stand.
`All right.
`THE COURT:
`Dr. Tullius is an
`MR. ZULLOW:
`expert in transplant surgery and
`immunosuppression and he'll be testifying about
`the invalidity of the '124 and '518 patents and
`he'll provide some information about what was
`known in the art in 1992, October of 1992.
`THE COURT:
`Okay.
`... STEFAN TULLIUS, having been
`duly sworn as a witness, was examined
`and testified as follows...
`MR. ZULLOW:
`Your Honor, may I
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`
`NOVARTIS EXHIBIT 2132
`Par v Novartis, IPR 2016-00084
`Page 2 of 3
`
`
`
`Tullius - cross
`
`1308
`
`BY MR. LOH:
`As of today, patients will better
`Q.
`adhere to an immunosuppressant drug regimen in
`which the drugs can be coadministered at the
`same time; is that correct?
`Can you please repeat the
`A.
`
`question?
`
`As of today, patients will better
`Q.
`adhere to an immunosuppressant drug regimen in
`which the drugs can be co-administered at the
`same time?
`Correct.
`A.
`By contrast, taking drugs four
`Q.
`hours apart will not result in a treatment
`regimen that you want?
`That will be much more difficult
`A.
`for a patient to take this treatment, yes.
`Dr. Tullius, I want to leave the
`Q.
`'772 patent behind now and talk about the '518
`and '124 patents.
`Okay?
`Mm-hmm.
`A.
`And before we begin this
`Q.
`discussion of the '518 and '124 patents, you
`understand that a person of ordinary skill in
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`
`NOVARTIS EXHIBIT 2132
`Par v Novartis, IPR 2016-00084
`Page 3 of 3